Evidence map›Paper›PMID 38917143›Full record

Observational studyPloS one2024

Screening outcome of HPV-vaccinated women: Data from the Danish Trial23 cohort study.

Mette Hartmann Nonboe, George Maria Napolitano, Caroline Kann, Berit Andersen, Mary Holten Bennetsen, Sanne Christiansen, Anna Poulsgaard Frandsen, Carsten Rygaard, Rouzbeh Salmani, Jeppe Bennekou Schroll and 1 more

Abstract readObservational Study
In one paragraph

Observational study in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Human papillomavirus prevalence in first, second and third cervical cell samples from women HPV-vaccinated as girls, Denmark, 2017 to 2024: data from the Trial23 cohort study.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mette Hartmann NonboeCentre for Health Research, Zealand University Hospital, Nykøbing Falster, Nykøbing Falster, Denmark.ORCID 0000-0003-0085-9109
George Maria NapolitanoDepartment of Public Health, University of Copenhagen, Copenhagen, Denmark.
Caroline KannDepartment of Gynaecology, Rigshospitalet, Copenhagen, Denmark.
Berit AndersenUniversity Research Clinic for Cancer Screening, Department of Public Health Programmes, Randers Regional Hospital, Randers, Denmark.ORCID 0000-0003-4074-6504
Mary Holten BennetsenDepartment of Pathology, Randers Regional Hospital, Randers, Denmark.
Sanne ChristiansenDepartment of Pathology, Sydvestjysk Hospital, Esbjerg, Denmark.
Anna Poulsgaard FrandsenDepartment of Pathology, Aalborg University Hospital, Aalborg, Denmark.
Carsten RygaardCentre for Health Research, Zealand University Hospital, Nykøbing Falster, Nykøbing Falster, Denmark.
Rouzbeh SalmaniDepartment of Pathology, Zealand University Hospital, Roskilde, Roskilde, Denmark.
Jeppe Bennekou SchrollDepartment of Gynaecology and Obstetrics, Herlev Gentofte University Hospital, Herlev, Denmark.
Elsebeth LyngeCentre for Health Research, Zealand University Hospital, Nykøbing Falster, Nykøbing Falster, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDanish women-who were HPV-vaccinated as girls-are now reaching an age where they are invited to cervical cancer screening. Because of their expected lower cervical cancer risk, we must reassess our screening strategies. We analyzed Danish HPV-vaccinated women's outcomes after the first screening test at age 23. METHODS AND

findingsOur study was embedded in Danish routine cytology-based screening. We conducted an observational study and included women born in 1994, offered the 4-valent HPV vaccine at age 14, and subsequently invited to screening at age 23. Cervical cytology was used for diagnostics and clinical management. Residual material was HPV tested with Cobas® 4800/6800. The most severe histology diagnosis within 795 days of screening was found through linkage with the Danish National Pathology Register. We calculated the number of women undergoing follow-up (repeated testing and/or colposcopy) per detected cervical intraepithelial neoplasia (CIN2+). A total of 6021 women were screened; 92% were HPV-vaccinated; 12% had abnormal cytology; 35% were high-risk HPV-positive, including 0.9% HPV16/18 positive, and 20% had follow-up. In women that were cytology-abnormal and HPV-positive (Cyt+/HPV+), 610 (98.5%) had been followed up, and 138 CIN2+ cases were diagnosed, resulting in 4.4 (95% CI 3.9-5.2) women undergoing follow-up per detected CIN2+. In contrast to recommendations, 182 (12.2%) cytology-normal and HPV-positive (Cyt-/HPV+) women were followed up within 795 days, and 8 CIN2+ cases were found, resulting in 22.8 (95% CI 13.3-59.3) women undergoing follow-up per detected CIN2+.

conclusionOverall, HPV prevalence was high in HPV-vaccinated women, but HPV16/18 had largely disappeared. In the large group of cytology-normal and HPV-positive women, 23 had been followed up per detected CIN2+ case. Our data indicated that primary HPV screening of young HPV-vaccinated women would require very effective triage methods to avoid an excessive follow-up burden.

trial registrationTrial registration number: NCT0304955.

Indexed as

Early Detection of CancerPapillomavirus InfectionsPapillomavirus VaccinesUterine Cervical NeoplasmsAdolescentAdultCohort StudiesDenmarkFemaleHuman papillomavirus 18HumansMass ScreeningUterine Cervical DysplasiaVaccinationYoung AdultPapillomavirus Vaccines

Identifiers

PMID38917143
PMCPMC11198772

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.